Non-opioid analgesic EC5026 for neuropathic pain: FDA-granted fast-track designation

EicOsis has developed a new class of oral non-opioid analgesis EC5026 by inhibiting soluble ephemoyxases (sEH)EC5026, which treats neuropathic pain, has recently been designated by the U.SFood and Drug Administration (FDA) for fast-trackFast-track designations can bring important benefits, including potential eligibility for priority review of new drug applicationsEC5026 is an oral small molecule that inhibits sEH, a key regulatory enzyme for endogenous anti-inflammatory fatty acid metabolismInhibition of sEH can treat pain by preventing the breakdown of these natural pain relief and anti-inflammatory fatty acids, causing the accumulation of fatty acids within cellsSEH inhibitors developed by EicOsis have shown in animal trials the benefits of reducing inflammation and neuropathic pain, without potential addictive or side effects associated with opioids or nonsteroidal anti-inflammatory drugs, and reducing pathological pain from natural seizures in horses, dogs and catsEC5026 received FDA IND approval in October 2019 and is currently conducting Phase 1a clinical trials in healthy volunteers, with EicOsis planning to advance Phase 1b clinical trials in the fall of 2020it is estimated that neuropathic pain affects 7-10% of the total population, greatly affecting people's daily function and quality of lifeoften prescribe opioids to patients with neurological pain to control symptoms, often associated with the risk of opioid abuse and addictionAs an effective analgesic, EC5026 has great potential to treat pain and reduce the use of prescription opioids as an effective, non-addictive alternative